Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
pharmathene.com

See what CB Insights has to offer

Competitors

15

Business Relationships

3

Service Providers

3

PharmAthene Competitors & Alternatives

15 Competitors

PharmAthene has 15 competitors. PharmAthene's competitors are Merus, Humanetics Corporation, Symphogen, Altor BioScience, Theraclone Sciences and more.

Latest Funding

Companies

Investment Stage

Total Funding

Mosaic
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

Location

1/19/2021

Corporate Minority - P2P

$145.5M

Netherlands

7/23/2020

Grant - III

$0.64M

Minnesota

11/30/2017

Project Finance

$364.16M

Denmark

3/22/2017

Series H

$105.04M

Florida

5/7/2015

Series C

$63.75M

Washington

8/19/2010

Nuon Therapeutics

Unattributed VC

$62.75M

California

8/21/2009

Micromet

PIPE - II

$128.66M

Maryland

8/21/2009

Immune Control

Series A - II

$17.75M

Pennsylvania

7/6/2009

Somaxon Pharmaceuticals

PIPE

$88M

California

10/17/2006

Tacere Therapeutics

Seed VC

California

Latest Funding

1/19/2021

7/23/2020

11/30/2017

3/22/2017

5/7/2015

8/19/2010

8/21/2009

8/21/2009

7/6/2009

10/17/2006

Companies

Nuon Therapeutics

Micromet

Immune Control

Somaxon Pharmaceuticals

Tacere Therapeutics

Investment Stage

Corporate Minority - P2P

Grant - III

Project Finance

Series H

Series C

Unattributed VC

PIPE - II

Series A - II

PIPE

Seed VC

Total Funding

$145.5M

$0.64M

$364.16M

$105.04M

$63.75M

$62.75M

$128.66M

$17.75M

$88M

Mosaic

Location

Netherlands

Minnesota

Denmark

Florida

Washington

California

Maryland

Pennsylvania

California

California

PharmAthene Service Providers

3 Service Providers

PharmAthene has 3 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Series C

Accounting Firm

Auditor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Series C

Subscribe to see more

Subscribe to see more

Provider Type

Accounting Firm

Subscribe to see more

Subscribe to see more

Service Type

Auditor

Subscribe to see more

Subscribe to see more

Partnership data by VentureSource

PharmAthene Partners & Customers

3 Partners and customers

PharmAthene has 3 strategic partners and customers. PharmAthene recently partnered with National Institute of Allergy and Infectious Diseases on May 5, 2017.

Date

Type

Business Partner

Country

News Snippet

Sources

5/3/2017

Partner

National Institute of Allergy and Infectious Diseases

United States

PharmAthene Reports Q1 2017 Financial and Operational Results

On September 9 , 2014 , PharmAthene , Inc. entered into an incrementally funded contract with the National Institutes of Allergy and Infectious Diseases for the development of a next generation lyophilized anthrax vaccine which provided for potential aggregate funding of up to approximately $ 28.1 million , if all technical milestones were met and all eight contract options were exercised by NIAID .

2

7/8/2015

Partner

Immunovaccine

Canada

Subscribe to see more

Subscribe to see more

10

1/1/2003

Client

US Government

United States

Subscribe to see more

Subscribe to see more

10

Date

5/3/2017

7/8/2015

1/1/2003

Type

Partner

Partner

Client

Business Partner

National Institute of Allergy and Infectious Diseases

Immunovaccine

US Government

Country

United States

Canada

United States

News Snippet

PharmAthene Reports Q1 2017 Financial and Operational Results

On September 9 , 2014 , PharmAthene , Inc. entered into an incrementally funded contract with the National Institutes of Allergy and Infectious Diseases for the development of a next generation lyophilized anthrax vaccine which provided for potential aggregate funding of up to approximately $ 28.1 million , if all technical milestones were met and all eight contract options were exercised by NIAID .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.